Kadmon Holdings Inc (NASDAQ:KDMN)‘s stock had its “buy” rating reiterated by equities research analysts at Piper Jaffray Companies in a report issued on Friday. They currently have a $7.00 price target on the stock. Piper Jaffray Companies’ target price suggests a potential upside of 129.51% from the company’s current price.
A number of other equities analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Kadmon Holdings from a “buy” rating to a “hold” rating and set a $4.25 price target on the stock. in a research note on Tuesday, June 27th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Kadmon Holdings in a research note on Monday, June 26th. Citigroup Inc. dropped their price target on shares of Kadmon Holdings from $6.00 to $4.00 and set a “neutral” rating on the stock in a research note on Monday, March 27th. Finally, WBB Securities upgraded shares of Kadmon Holdings from a “sell” rating to a “hold” rating and set a $3.25 price target on the stock in a research note on Thursday, March 16th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $9.93.
Kadmon Holdings (NASDAQ:KDMN) opened at 3.05 on Friday. The firm has a 50 day moving average of $2.80 and a 200-day moving average of $3.58. The company’s market capitalization is $158.13 million. Kadmon Holdings has a 1-year low of $2.25 and a 1-year high of $11.73.
Kadmon Holdings (NASDAQ:KDMN) last released its earnings results on Monday, May 15th. The company reported ($0.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.13. The business had revenue of $5.60 million during the quarter, compared to analysts’ expectations of $4.25 million. The firm’s revenue was down 42.3% on a year-over-year basis. On average, equities research analysts anticipate that Kadmon Holdings will post ($1.67) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Kadmon Holdings Inc (NASDAQ:KDMN) Stock Rating Reaffirmed by Piper Jaffray Companies” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://sportsperspectives.com/2017/07/18/kadmon-holdings-inc-nasdaqkdmn-stock-rating-reaffirmed-by-piper-jaffray-companies.html.
In related news, major shareholder Goldentree Asset Management Lp sold 767,363 shares of the company’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $3.50, for a total value of $2,685,770.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 1,490,670 shares of company stock worth $5,284,489.
A number of institutional investors have recently made changes to their positions in the company. Perceptive Advisors LLC boosted its position in shares of Kadmon Holdings by 134.7% in the first quarter. Perceptive Advisors LLC now owns 5,185,847 shares of the company’s stock worth $18,772,000 after buying an additional 2,976,190 shares during the last quarter. KCG Holdings Inc. bought a new position in Kadmon Holdings during the first quarter valued at about $124,000. Renaissance Technologies LLC bought a new position in Kadmon Holdings during the first quarter valued at about $158,000. AE Wealth Management LLC bought a new position in Kadmon Holdings during the first quarter valued at about $391,000. Finally, JPMorgan Chase & Co. boosted its position in Kadmon Holdings by 11,654.8% in the first quarter. JPMorgan Chase & Co. now owns 228,866 shares of the company’s stock valued at $829,000 after buying an additional 226,919 shares in the last quarter.
Kadmon Holdings Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.